Skip to content
Evigrade
ModerateNon-steroidal anti-inflammatory drug, propionic acid derivative, for topical throat treatment×Angiotensin II receptor blocker (ARB, sartan)

Updated · Methodology

Mechanism

Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis (flurbiprofen SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). In combination, NSAIDs and angiotensin II receptor antagonists, the class that includes olmesartan, may reduce glomerular filtration. The risk of this combination is acute renal failure (olmesartan SmPC, AEMPS, section 4.5). The combination may also reduce the antihypertensive effect of olmesartan (olmesartan SmPC, AEMPS, section 4.5; olmesartan label, US Food and Drug Administration, FDA, section 7.2). When flurbiprofen is taken as a lozenge, it is absorbed quickly into the blood. Its peak plasma concentration, however, stays low: about 1.4 µg/mL, roughly 4.4 times lower than after a 50 mg flurbiprofen tablet (flurbiprofen SmPC, AEMPS, section 5.2). The elimination routes do not overlap. No other significant metabolites of olmesartan were found, and olmesartan is excreted in the urine (about 40%) and in bile (about 60%). Hydroxylation is the main metabolic pathway of flurbiprofen, which is excreted in the urine (olmesartan and flurbiprofen SmPCs, AEMPS, section 5.2).

Symptoms

The documents describe no symptoms specific to this combination. Possible signs are a weaker blood-pressure-lowering effect of olmesartan and worsening renal function, up to acute renal failure. Renal function is especially at risk in older people, in people with volume depletion, including those on diuretics, and in people with impaired renal function (olmesartan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5; olmesartan label, US Food and Drug Administration, FDA, section 7.2). According to the flurbiprofen SmPC, the renal complications of non-steroidal anti-inflammatory drugs are not usually seen with limited, short-term use of flurbiprofen lozenges (flurbiprofen SmPC, AEMPS, section 4.4).

Management

The combination is acceptable with caution. The flurbiprofen SmPC explicitly names angiotensin II receptor antagonists, the class that includes olmesartan, among drugs that require caution when combined with flurbiprofen. It also asks that the person stay adequately hydrated (flurbiprofen SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). When olmesartan is combined with non-steroidal anti-inflammatory drugs (NSAIDs), its SmPC recommends monitoring renal function at the start of treatment and regular hydration (olmesartan SmPC, AEMPS, section 4.5). The US olmesartan label recommends periodic monitoring of renal function (olmesartan label, US Food and Drug Administration, FDA, section 7.2). One flurbiprofen lozenge is dissolved in the mouth every 3–6 hours, with no more than 5 lozenges in 24 hours. The SmPC recommends using them for no longer than 3 days, at the lowest effective dose and for the shortest possible time (flurbiprofen SmPC, AEMPS, sections 4.2 and 4.4). In people with a history of hypertension or heart failure, flurbiprofen needs a separate assessment before use, because fluid retention, hypertension and oedema have been reported with NSAIDs (flurbiprofen SmPC, AEMPS, section 4.4). Flurbiprofen is contraindicated in severe renal failure (flurbiprofen SmPC, AEMPS, section 4.3), and olmesartan is not recommended when creatinine clearance is below 20 mL/min (olmesartan SmPC, AEMPS, section 4.4).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Olmesartan medoxomil